A Food and Drug Administration (FDA) advisory committee says long-acting beta-2 agonist (LABA) inhalers used alone are too risky for children younger than 18. The decision is still out on whether the benefits outweigh the risks for adults who use an LABA drug for daily treatment of asthma. Read more »